| Structure-guided design and optimization of small molecules targeting the protein–protein interaction between the von Hippel–Lindau (VHL) E3 ubiquitin ligase and the hypoxia … C Galdeano, MS Gadd, P Soares, S Scaffidi, I Van Molle, I Birced, ... Journal of Medicinal Chemistry 57 (20), 8657-8663, 2014 | 396 | 2014 |
| Novel donepezil-based inhibitors of acetyl-and butyrylcholinesterase and acetylcholinesterase-induced β-amyloid aggregation P Camps, X Formosa, C Galdeano, T Gómez, D Munoz-Torrero, ... Journal of medicinal chemistry 51 (12), 3588-3598, 2008 | 243 | 2008 |
| Pyrano[3,2-c]quinoline−6-Chlorotacrine Hybrids as a Novel Family of Acetylcholinesterase- and β-Amyloid-Directed Anti-Alzheimer Compounds P Camps, X Formosa, C Galdeano, D Munoz-Torrero, L Ramirez, ... Journal of medicinal chemistry 52 (17), 5365-5379, 2009 | 230 | 2009 |
| Potent and selective chemical probe of hypoxic signalling downstream of HIF-α hydroxylation via VHL inhibition J Frost, C Galdeano, P Soares, MS Gadd, KM Grzes, L Ellis, O Epemolu, ... Nature communications 7 (1), 13312, 2016 | 198 | 2016 |
| Group-based optimization of potent and cell-active inhibitors of the von Hippel–Lindau (VHL) E3 ubiquitin ligase: structure–activity relationships leading to the chemical probe … P Soares, MS Gadd, J Frost, C Galdeano, L Ellis, O Epemolu, S Rocha, ... Journal of medicinal chemistry 61 (2), 599-618, 2018 | 138 | 2018 |
| Huprine–tacrine heterodimers as anti-amyloidogenic compounds of potential interest against Alzheimer’s and prion diseases C Galdeano, E Viayna, I Sola, X Formosa, P Camps, A Badia, MV Clos, ... Journal of medicinal chemistry 55 (2), 661-669, 2012 | 118 | 2012 |
| Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates P Camps, X Formosa, C Galdeano, T Gómez, D Muñoz-Torrero, ... Chemico-biological interactions 187 (1-3), 411-415, 2010 | 111 | 2010 |
| Novel Huprine Derivatives with Inhibitory Activity toward β‐Amyloid Aggregation and Formation as Disease‐Modifying Anti‐Alzheimer Drug Candidates E Viayna, T Gómez, C Galdeano, L Ramírez, M Ratia, A Badia, MV Clos, ... ChemMedChem 5 (11), 1855-1870, 2010 | 74 | 2010 |
| Is NMR fragment screening fine-tuned to assess druggability of protein–protein interactions? DM Dias, I Van Molle, MGJ Baud, C Galdeano, CFGC Geraldes, A Ciulli ACS medicinal chemistry letters 5 (1), 23-28, 2014 | 68 | 2014 |
| Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer’s disease C Griñán-Ferré, S Codony, E Pujol, J Yang, R Leiva, C Escolano, ... Neurotherapeutics 17, 1825-1835, 2020 | 66 | 2020 |
| Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology C Galdeano, A Ciulli Future medicinal chemistry 8 (13), 1655-1680, 2016 | 65 | 2016 |
| Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents C Galdeano, E Viayna, P Arroyo, A Bidon-Chanal, J Ramon Blas, ... Current pharmaceutical design 16 (25), 2818-2836, 2010 | 63 | 2010 |
| Shogaol–huprine hybrids: dual antioxidant and anticholinesterase agents with β-amyloid and tau anti-aggregating properties FJ Pérez-Areales, O Di Pietro, A Espargaró, A Vallverdú-Queralt, ... Bioorganic & Medicinal Chemistry 22 (19), 5298-5307, 2014 | 56 | 2014 |
| Thioflavin-S staining of bacterial inclusion bodies for the fast, simple, and inexpensive screening of amyloid aggregation inhibitors S Pouplana, A Espargaro, C Galdeano, E Viayna, I Sola, S Ventura, ... Current Medicinal Chemistry 21 (9), 1152-1159, 2014 | 52 | 2014 |
| Increasing polarity in tacrine and huprine derivatives: Potent anticholinesterase agents for the treatment of myasthenia gravis C Galdeano, N Coquelle, M Cieslikiewicz-Bouet, M Bartolini, B Pérez, ... Molecules 23 (3), 634, 2018 | 33 | 2018 |
| Oxygen uptake rate measurements both by the dynamic method and during the process growth of Rhodococcus erythropolis IGTS8: Modelling and difference in results VE Santos, C Galdeano, E Gomez, A Alcon, F Garcia-Ochoa Biochemical Engineering Journal 32 (3), 198-204, 2006 | 32 | 2006 |
| Drugging the undruggable: targeting challenging E3 ligases for personalized medicine C Galdeano Future Medicinal Chemistry 9 (4), 347-350, 2017 | 28 | 2017 |
| Highly Diastereoselective One-Pot Synthesis of Spiro{cyclopenta[a]indene-2,2‘-indene}diones from 1-Indanones and Aromatic Aldehydes P Camps, LR Domingo, X Formosa, C Galdeano, D González, ... The Journal of Organic Chemistry 71 (9), 3464-3471, 2006 | 27 | 2006 |
| Unveiling the multitarget anti-Alzheimer drug discovery landscape: A bibliometric analysis A Sampietro, FJ Pérez-Areales, P Martínez, EM Arce, C Galdeano, ... Pharmaceuticals 15 (5), 545, 2022 | 26 | 2022 |
| Soluble epoxide hydrolase inhibition to face neuroinflammation in Parkinson’s disease: A new therapeutic strategy M Pallàs, S Vázquez, C Sanfeliu, C Galdeano, C Griñán-Ferré Biomolecules 10 (5), 703, 2020 | 25 | 2020 |
